Healthcare Providers and Services
Company Overview of Beth Israel Deaconess Medical Center, Inc.
Beth Israel Deaconess Medical Center, Inc. operates a hospital in Massachusetts. It offers cancer, chest and digestive disease, and spine center services, as well as transplant institute and nursing services. The company also provides Biomedical Research, such as vascular and transplantation research, signal transduction in cancer, and molecular imaging services. In addition, it offers nursing, social work, and health sciences training to medical students, interns, residents, and professionals, as well as graduate and undergraduate medical education services. The company was founded as The Beth Israel Hospital Association in 1915 and changed its name to Beth Israel Deaconess Medical Center, ...
330 Brookline Avenue
Boston, MA 02215
Founded in 1915
Key Executives for Beth Israel Deaconess Medical Center, Inc.
President and Chief Executive Officer
Chief of Department of Medicine
Chairman of Obstetrics & Gynecology Departments
Chief of Clinical Research and Cardiovascular Division and Associate Professor of Medicine
Vice President of Research Operations
Compensation as of Fiscal Year 2016.
Beth Israel Deaconess Medical Center, Inc. Key Developments
Beth Israel Deaconess Medical Center, Inc. Appoints Peter Healy as President
May 31 16
Beth Israel Deaconess Medical Center announced that it would create several new executive positions around the Longwood hospital, creating two new positions - a president and chief financial officer - to oversee the system. Peter Healy, currently the CEO of Beth Israel's Milton hospital, has been appointed president. Meanwhile, Beth
Israel's CEO, Dr. Kevin Tabb, will shift his focus to organizational growth, which includes yet-to-be-released details on a fundraising campaign to support research efforts and institutional improvements.
Leon V. & Marilyn L. Rosenberg Clinical Cancer Center Appoints Manuel Hidalgo as Clinical Director and Chief of the Hospital’s Division of Hematology-Oncology
Nov 10 15
PharmaCyte Biotech, Inc. announced that Manuel Hidalgo, MD, PhD, an internationally respected oncologist and a member of PharmaCyte ’s Scientific Advisory Board, has been named Clinical Director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center, part of the Cancer Center at the Beth Israel Deaconess Medical Center (BIDMC) in Boston. Dr. Hidalgo has also been appointed Chief of the hospital’s Division of Hematology-Oncology. In his role at the prestigious medical center, Dr. Hidalgo will oversee all of BIDMC’s clinical cancer programs. Dr. Hidalgo, whose groundbreaking work in experimental cancer therapy and tumor model development has led to key advances in the treatment of pancreatic cancer, will join the BIDMC this month. He is currently serving as the Director of the Clinical Research Program and Vice Director of Translational Research at the Spanish National Cancer Center. Dr. Hidalgo also holds faculty positions at University CEU San Pablo and Johns Hopkins University.
Beth Israel Deaconess Medical Center Announces New Center for Outcomes Research in Cardiology; Appoints Robert W. Yeh as Director of the Smith Center
Nov 2 15
Beth Israel Deaconess Medical Center announced the launch of a new research center that will use rigorous scientific methods to evaluate and transform the delivery of care for cardiovascular conditions in the United States. The Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology at Beth Israel Deaconess Medical Center (BIDMC) will bring together clinicians and researchers to examine the most pressing challenges in cardiovascular care, including clinical effectiveness, cost, quality, ethics and public policy.
Robert W. Yeh, MD, MSc, MBA, has been named Director of the Smith Center. A national leader in cardiovascular outcomes research and an interventional cardiologist specializing in complex coronary interventions, Yeh joins BIDMC from Massachusetts General Hospital (MGH). Yeh has led seminal research using electronic health record data to inform cardiovascular epidemiology and improve clinical risk prediction to maximize procedural value. He is an expert in the use of observational research methods in examining comparative effectiveness and evaluating health policy. In addition to his leadership of the Smith Center, he will maintain a clinical cardiology practice at the CardioVascular Institute at BIDMC and will continue to serve as Medical Director of Trial Design at the Harvard Clinical Research Institute.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|